Vincerx Pharma, Inc.
VINC
$0.8341
$0.01962.41%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 7.56% | 23.61% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 5.80% | -1.50% | |||
| Operating Income | -5.80% | 1.50% | |||
| Income Before Tax | -333.79% | 85.45% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -333.79% | 85.45% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -333.79% | 85.45% | |||
| EBIT | -5.80% | 1.50% | |||
| EBITDA | -5.81% | 1.50% | |||
| EPS Basic | -312.89% | 89.58% | |||
| Normalized Basic EPS | -312.96% | 89.58% | |||
| EPS Diluted | -312.89% | 89.58% | |||
| Normalized Diluted EPS | -312.96% | 89.58% | |||
| Average Basic Shares Outstanding | 5.11% | 39.58% | |||
| Average Diluted Shares Outstanding | 5.11% | 39.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
